Peter J Leary, Samuel G Rayner, Kelley R H Branch, Laurie Hogl, Nancy M Liston, Lia M Barros, Jessi Prout, Stephanie Nolley, Jonathan Buber, David D Ralph, Jeffrey L Probstfield
{"title":"法莫替丁对肺动脉高压预后的影响：一项随机对照试验。","authors":"Peter J Leary, Samuel G Rayner, Kelley R H Branch, Laurie Hogl, Nancy M Liston, Lia M Barros, Jessi Prout, Stephanie Nolley, Jonathan Buber, David D Ralph, Jeffrey L Probstfield","doi":"10.1016/j.chest.2024.12.029","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Adaptation of the right ventricle is a key determinant of outcomes in pulmonary arterial hypertension (PAH). Despite a compelling rationale to develop targeted therapies for the right ventricle in PAH, no such treatments exist. H<sub>2</sub>-receptor antagonism is a potential myocardial-focused paradigm in heart failure.</p><p><strong>Research question: </strong>Do H<sub>2</sub>-receptor antagonists improve outcomes in participants with PAH?</p><p><strong>Study design and methods: </strong>We conducted a 24-week, single-center, 1:1 randomized, double-blind, placebo-controlled trial of the H<sub>2</sub>-receptor antagonist famotidine in patients with a diagnosis of PAH. The primary outcome was change in six-minute walk distance (6MWD) at 24 weeks. Secondary endpoints included B-type natriuretic peptide levels, NYHA functional class, right ventricular parameters, health-related quality of life, and escalation in PAH-focused care.</p><p><strong>Results: </strong>From May 2019 to July 2023, 80 participants were randomized with 79 receiving study drug. There was no significant difference in the primary outcome of 6MWD at 24 weeks, with an increase of 4.7 meters seen in the placebo arm versus a decrease of 17.0 meters in the famotidine arm (p = 0.24). There were also no differences in secondary endpoints at 24 weeks. Study drug was well tolerated, and safety profiles were similar between arms. Adherence and study conduct was good overall. Participants with methamphetamine-associated PAH were similar in all aspects to the study participants more broadly.</p><p><strong>Interpretation: </strong>The results of this trial do not support the routine use of famotidine 20 mg daily as an adjunct therapy for the treatment of PAH. The REHAB-PH trial argues against the practice of avoiding participants with methamphetamine-associated PAH in randomized clinical trials of novel therapies.</p><p><strong>Clinical trials registration: </strong>The trial was registered at clinicaltrials.gov (NCT03554291).</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.5000,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of famotidine on outcomes in pulmonary arterial hypertension: A randomized controlled trial.\",\"authors\":\"Peter J Leary, Samuel G Rayner, Kelley R H Branch, Laurie Hogl, Nancy M Liston, Lia M Barros, Jessi Prout, Stephanie Nolley, Jonathan Buber, David D Ralph, Jeffrey L Probstfield\",\"doi\":\"10.1016/j.chest.2024.12.029\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Adaptation of the right ventricle is a key determinant of outcomes in pulmonary arterial hypertension (PAH). Despite a compelling rationale to develop targeted therapies for the right ventricle in PAH, no such treatments exist. H<sub>2</sub>-receptor antagonism is a potential myocardial-focused paradigm in heart failure.</p><p><strong>Research question: </strong>Do H<sub>2</sub>-receptor antagonists improve outcomes in participants with PAH?</p><p><strong>Study design and methods: </strong>We conducted a 24-week, single-center, 1:1 randomized, double-blind, placebo-controlled trial of the H<sub>2</sub>-receptor antagonist famotidine in patients with a diagnosis of PAH. The primary outcome was change in six-minute walk distance (6MWD) at 24 weeks. Secondary endpoints included B-type natriuretic peptide levels, NYHA functional class, right ventricular parameters, health-related quality of life, and escalation in PAH-focused care.</p><p><strong>Results: </strong>From May 2019 to July 2023, 80 participants were randomized with 79 receiving study drug. There was no significant difference in the primary outcome of 6MWD at 24 weeks, with an increase of 4.7 meters seen in the placebo arm versus a decrease of 17.0 meters in the famotidine arm (p = 0.24). There were also no differences in secondary endpoints at 24 weeks. Study drug was well tolerated, and safety profiles were similar between arms. Adherence and study conduct was good overall. Participants with methamphetamine-associated PAH were similar in all aspects to the study participants more broadly.</p><p><strong>Interpretation: </strong>The results of this trial do not support the routine use of famotidine 20 mg daily as an adjunct therapy for the treatment of PAH. The REHAB-PH trial argues against the practice of avoiding participants with methamphetamine-associated PAH in randomized clinical trials of novel therapies.</p><p><strong>Clinical trials registration: </strong>The trial was registered at clinicaltrials.gov (NCT03554291).</p>\",\"PeriodicalId\":9782,\"journal\":{\"name\":\"Chest\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":9.5000,\"publicationDate\":\"2025-01-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chest\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.chest.2024.12.029\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chest","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.chest.2024.12.029","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
Effect of famotidine on outcomes in pulmonary arterial hypertension: A randomized controlled trial.
Background: Adaptation of the right ventricle is a key determinant of outcomes in pulmonary arterial hypertension (PAH). Despite a compelling rationale to develop targeted therapies for the right ventricle in PAH, no such treatments exist. H2-receptor antagonism is a potential myocardial-focused paradigm in heart failure.
Research question: Do H2-receptor antagonists improve outcomes in participants with PAH?
Study design and methods: We conducted a 24-week, single-center, 1:1 randomized, double-blind, placebo-controlled trial of the H2-receptor antagonist famotidine in patients with a diagnosis of PAH. The primary outcome was change in six-minute walk distance (6MWD) at 24 weeks. Secondary endpoints included B-type natriuretic peptide levels, NYHA functional class, right ventricular parameters, health-related quality of life, and escalation in PAH-focused care.
Results: From May 2019 to July 2023, 80 participants were randomized with 79 receiving study drug. There was no significant difference in the primary outcome of 6MWD at 24 weeks, with an increase of 4.7 meters seen in the placebo arm versus a decrease of 17.0 meters in the famotidine arm (p = 0.24). There were also no differences in secondary endpoints at 24 weeks. Study drug was well tolerated, and safety profiles were similar between arms. Adherence and study conduct was good overall. Participants with methamphetamine-associated PAH were similar in all aspects to the study participants more broadly.
Interpretation: The results of this trial do not support the routine use of famotidine 20 mg daily as an adjunct therapy for the treatment of PAH. The REHAB-PH trial argues against the practice of avoiding participants with methamphetamine-associated PAH in randomized clinical trials of novel therapies.
Clinical trials registration: The trial was registered at clinicaltrials.gov (NCT03554291).
期刊介绍：
At CHEST, our mission is to revolutionize patient care through the collaboration of multidisciplinary clinicians in the fields of pulmonary, critical care, and sleep medicine. We achieve this by publishing cutting-edge clinical research that addresses current challenges and brings forth future advancements. To enhance understanding in a rapidly evolving field, CHEST also features review articles, commentaries, and facilitates discussions on emerging controversies. We place great emphasis on scientific rigor, employing a rigorous peer review process, and ensuring all accepted content is published online within two weeks.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
